S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
The 4 highest-shorted large-cap stocks
The top-rated strong-buy stocks on Marketbeat’s radar
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
What’s next for GM stock: Buybacks and a dividend increase
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
The 4 highest-shorted large-cap stocks
The top-rated strong-buy stocks on Marketbeat’s radar
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
What’s next for GM stock: Buybacks and a dividend increase
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
The 4 highest-shorted large-cap stocks
The top-rated strong-buy stocks on Marketbeat’s radar
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
What’s next for GM stock: Buybacks and a dividend increase
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
The 4 highest-shorted large-cap stocks
The top-rated strong-buy stocks on Marketbeat’s radar
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
What’s next for GM stock: Buybacks and a dividend increase
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023

Eledon Pharmaceuticals (ELDN) Competitors

$1.12
-0.08 (-6.67%)
(As of 11/29/2023 ET)
Compare
Today's Range
$1.11
$1.19
50-Day Range
$1.12
$1.69
52-Week Range
$1.07
$3.70
Volume
50,809 shs
Average Volume
86,500 shs
Market Capitalization
$27.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

ELDN vs. KRRO, EFTR, UBX, XLO, RGLS, SLS, GANX, SLGL, CLRB, and RZLT

Should you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Korro Bio (KRRO), eFFECTOR Therapeutics (EFTR), Unity Biotechnology (UBX), Xilio Therapeutics (XLO), Regulus Therapeutics (RGLS), SELLAS Life Sciences Group (SLS), Gain Therapeutics (GANX), Sol-Gel Technologies (SLGL), Cellectar Biosciences (CLRB), and Rezolute (RZLT). These companies are all part of the "pharmaceutical preparations" industry.

Eledon Pharmaceuticals vs.

Korro Bio (NASDAQ:KRRO) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations.

Korro Bio currently has a consensus target price of $125.00, suggesting a potential upside of 211.10%. Eledon Pharmaceuticals has a consensus target price of $10.67, suggesting a potential upside of 852.38%. Given Korro Bio's higher possible upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Korro Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Korro Bio
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Eledon Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Korro Bio has higher revenue and earnings than Eledon Pharmaceuticals. Korro Bio is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Korro Bio$14.07M2.08-$81.58M-$94.50-0.43
Eledon PharmaceuticalsN/AN/A-$87.97M-$5.59-0.20

In the previous week, Korro Bio had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 4 mentions for Korro Bio and 3 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.64 beat Korro Bio's score of 0.44 indicating that Korro Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Korro Bio
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Eledon Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 39.4% of Eledon Pharmaceuticals shares are owned by institutional investors. 16.8% of Korro Bio shares are owned by company insiders. Comparatively, 19.4% of Eledon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Eledon Pharmaceuticals received 21 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 69.70% of users gave Eledon Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Korro BioOutperform Votes
2
100.00%
Underperform Votes
No Votes
Eledon PharmaceuticalsOutperform Votes
23
69.70%
Underperform Votes
10
30.30%

Korro Bio has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.

Korro Bio's return on equity of -46.18% beat Eledon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Korro BioN/A -115.97% -68.09%
Eledon Pharmaceuticals N/A -46.18%-42.79%

Summary

Eledon Pharmaceuticals beats Korro Bio on 10 of the 15 factors compared between the two stocks.


Get Eledon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELDN vs. The Competition

MetricEledon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$27.10M$5.79B$4.41B$6.70B
Dividend YieldN/A3.09%2.90%6.97%
P/E Ratio-0.2011.88132.9113.20
Price / SalesN/A408.812,647.2396.63
Price / Cash1.7019.1684.57141.07
Price / Book0.304.185.375.07
Net Income-$87.97M$210.48M$122.90M$176.65M
7 Day Performance-6.67%2.21%2.05%1.93%
1 Month Performance-29.74%8.17%13.53%10.09%
1 Year Performance-54.29%4.37%5.79%2.98%

Eledon Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KRRO
Korro Bio
2.1555 of 5 stars
$38.64
+2.6%
$180.00
+365.8%
N/A$28.21M$14.07M-0.41N/AUpcoming Earnings
Analyst Report
High Trading Volume
EFTR
eFFECTOR Therapeutics
1.9717 of 5 stars
$0.66
+11.8%
$6.00
+805.3%
+18.6%$28.10M$3.55M-0.8715Insider Selling
Short Interest ↑
High Trading Volume
UBX
Unity Biotechnology
2.6491 of 5 stars
$2.06
+2.0%
$6.50
+215.5%
-28.4%$30.12M$240,000.00-0.5622Positive News
XLO
Xilio Therapeutics
2.3253 of 5 stars
$1.10
-9.1%
$8.50
+672.7%
-57.6%$30.30MN/A-0.3784Positive News
Gap Up
High Trading Volume
RGLS
Regulus Therapeutics
2.4495 of 5 stars
$1.37
-2.1%
$10.50
+666.4%
-24.6%$27.71M$10.01M-0.8630Positive News
SLS
SELLAS Life Sciences Group
1.6141 of 5 stars
$0.97
-1.0%
$3.00
+209.3%
-54.9%$31.10M$1M-0.6317Short Interest ↑
GANX
Gain Therapeutics
2.1798 of 5 stars
$2.07
-23.9%
$9.00
+334.8%
-26.2%$26.72M$55,180.00-1.1428Positive News
Gap Up
High Trading Volume
SLGL
Sol-Gel Technologies
2.3682 of 5 stars
$1.37
-2.1%
$8.00
+483.9%
-73.7%$31.69M$3.88M-1.2655News Coverage
CLRB
Cellectar Biosciences
1.4804 of 5 stars
$2.14
-0.9%
$10.00
+367.3%
+23.8%$26.30MN/A-0.6615Short Interest ↓
Negative News
RZLT
Rezolute
2.1794 of 5 stars
$0.80
+6.6%
$8.67
+977.4%
-55.0%$31.87MN/A-0.7451Gap Up

Related Companies and Tools

This page (NASDAQ:ELDN) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -